Company: RGNT
Filing Date: 2025-05-05
Form Type: F-1/A
Source: 0001213900-25-039589
Chunk: 25

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-05-05
Form: F-1/A
Chunk 25
---
 or when, or if, we will be able
to achieve or maintain profitability.

Even if this offering is successful, we will need to raise substantial additional funding, which may not be available on acceptable terms, or at all. Failure to obtain funding on acceptable terms and on a timely basis may require us to curtail, delay or discontinue our product development efforts or other operations.

As of December 31,
2024 and December 31, 2023, our cash and cash equivalents were approximately $0.2 million and $0.3 million, respectively, and we had
a negative working capital of approximately $5.5 million and $2.8 million, respectively, and an accumulated deficit of approximately
$41.7 million and $46.9 million, respectively. Based on our current plans, we believe that our existing cash and, cash equivalents
will be sufficient to enable us to fund our operating expenses and capital expenditure requirements through June 2025 without giving
effect to the proceeds from this offering. Even if this offering is completed, we expect that we will require substantial additional
capital to commercialize our Gelrin hydrogel platform and any future product candidates. In addition, our operating plans may change
as a result of many factors that may currently be unknown to us, and we may need to seek additional funds sooner than planned. Our
future funding requirements will depend on many factors, including but not limited to:

| ● | the progress, results and costs of our ongoing and planned studies and pivotal clinical trials; |

| ● | the cost, timing and outcomes of regulatory review of our Gelrin hydrogel platform and any future product candidates; |

<div align='center'>16</div>

| ● | the costs of manufacturing product candidates, including costs related to engaging third-party manufacturers therefor; |

| ● | the scope, progress, results and costs of product development, testing, manufacturing, preclinical development and, if applicable, clinical trials for any other product candidates that we may develop or otherwise obtain in the future; |

| ● | the cost of our future activities, including establishing sales, marketing and distribution capabilities for any product or product candidates in any particular geography where we receive marketing approval for such product candidates; |

| ● | the terms and timing of any collaborative, licensing and other arrangements that we may establish; |

| ● | the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims; and |

| ● | the level of